National Comprehensive Cancer Network® Favorable Intermediate Risk Prostate Cancer—Is Active Surveillance Appropriate?
暂无分享,去创建一个
Tara McLaughlin | I. Staff | Monty A. Aghazadeh | Jason Frankel | Matthew Belanger | Joseph Tortora | Ilene Staff | Joseph R. Wagner | J. Wagner | Tara McLaughlin | Jason K. Frankel | M. Belanger | Joseph Tortora
[1] Mufaddal Mamawala,et al. Intermediate and Longer-Term Outcomes From a Prospective Active-Surveillance Program for Favorable-Risk Prostate Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] Ronald C. Chen,et al. Active Surveillance for the Management of Localized Prostate Cancer (Cancer Care Ontario Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] David C. Miller,et al. Contemporary use of initial active surveillance among men in Michigan with low-risk prostate cancer. , 2015, European urology.
[4] H. G. van der Poel,et al. Can we expand active surveillance criteria to include biopsy Gleason 3+4 prostate cancer? A multi-institutional study of 2,323 patients. , 2015, Urologic oncology.
[5] Y. Yamada,et al. A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy. , 2013, European urology.
[6] Liying Zhang,et al. Active Surveillance for Intermediate Risk Prostate Cancer: Survival Outcomes in the Sunnybrook Experience. , 2016, The Journal of urology.
[7] J. Epstein,et al. Adverse Pathologic Findings for Men Electing Immediate Radical Prostatectomy: Defining a Favorable Intermediate-Risk Group , 2018, JAMA Oncology.
[8] Kirsten L. Greene,et al. The relationship between prostate specific antigen change and biopsy progression in patients on active surveillance for prostate cancer. , 2011, The Journal of urology.
[9] M. Cooperberg,et al. Trends in Management for Patients With Localized Prostate Cancer, 1990-2013. , 2015, JAMA.
[10] P. Carroll,et al. Active surveillance for prostate cancer: a narrative review of clinical guidelines , 2016, Nature Reviews Urology.
[11] A. Costello,et al. Feasibility for active surveillance in biopsy Gleason 3 + 4 prostate cancer: an Australian radical prostatectomy cohort , 2016, BJU international.
[12] Danny Vesprini,et al. Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] D. Siemens. Radical prostatectomy or watchful waiting in early prostate cancer? , 2003, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[14] P. Maté Mate. [Radical prostatectomy versus observation for localized prostate cancer]. , 2013, Revista clinica espanola.
[15] M. Roobol,et al. A Decade of Active Surveillance in the PRIAS Study: An Update and Evaluation of the Criteria Used to Recommend a Switch to Active Treatment. , 2016, European urology.
[16] Misop Han,et al. Predicting 15-year prostate cancer specific mortality after radical prostatectomy. , 2011, The Journal of urology.
[17] Rodolfo Montironi,et al. The contemporary concept of significant versus insignificant prostate cancer , 2011 .
[18] A. Evans,et al. Active surveillance for the management of localized prostate cancer: Guideline recommendations. , 2015, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.
[19] L. Egevad,et al. A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score. , 2016, European urology.
[20] Robert J Volk,et al. Physician variation in management of low-risk prostate cancer: a population-based cohort study. , 2014, JAMA internal medicine.
[21] T. Tammela,et al. Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly. , 2009, European urology.
[22] J. Hugosson,et al. Long-term Results of Active Surveillance in the Göteborg Randomized, Population-based Prostate Cancer Screening Trial. , 2016, European urology.
[23] M. Soloway,et al. Careful selection and close monitoring of low-risk prostate cancer patients on active surveillance minimizes the need for treatment. , 2010, European urology.
[24] David S. Yee,et al. Role of prostate specific antigen and immediate confirmatory biopsy in predicting progression during active surveillance for low risk prostate cancer. , 2011, The Journal of urology.